Myriad Genetics Inc
MYGN
ISIN null / Valor 338449
Myriad Genetics Inc
UMushroom community rating:
About company
Myriad Genetics is a Salt Lake City–based molecular diagnostics company that develops and commercializes laboratory tests and companion diagnostics to assess inherited risk, inform cancer treatment decisions and predict drug response; its offerings include hereditary cancer tests such as BRACAnalysis and the myRisk multi-gene panels, the myChoice CDx homologous recombination deficiency assay used to stratify patients for certain cancer therapies, the Prolaris prostate cancer prognostic test, and the GeneSight pharmacogenomic service for guiding psychiatric medication selection. The company operates a clinical laboratory business serving physicians, hospitals and payers, and generates additional revenue through partnerships and diagnostic licensing with biopharmaceutical firms; it is publicly traded on NASDAQ under the ticker MYGN.
Summarized from source with an LLMView SourceSector: TechnologyKey figures
Performance
Volatility
412 M
Market cap (USD)
1,367,872
Daily traded volume (Shares)
13.81 / 13.04
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
